Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Low-profile Cough/Cold/Allergy Meds Target Of Latest FDA Push Against Unapproved Rx Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency doesn't know the drugs' share of the market, but uncertainties about their safety and efficacy constitute an untenable risk for consumers, CDER compliance chief says.

You may also be interested in...



OTC Monograph Offers Redemption For Some Unapproved Cough/Cold Drugs

FDA could seize offending products or file injunctions against firms if the drugs were not listed with the agency before March 2 and firms do not discontinue production and shipping immediately.

OTC Monograph Offers Redemption For Some Unapproved Cough/Cold Drugs

FDA could seize offending products or file injunctions against firms if the drugs were not listed with the agency before March 2 and firms do not discontinue production and shipping immediately.

Pediatric Cough/Cold Products Relabeled “Do Not Use” For Children Under 4

Voluntary effort based on AE data for 2-3-year-olds.

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel